Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs WisdomTree Inc. Common Stock (WT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs WisdomTree Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while WisdomTree Inc. Common Stock trades at $21.02 (market cap $3.27B). The key difference: WisdomTree Inc. Common Stock is far larger — about 3.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and WisdomTree Inc. Common Stock pays a 0.56% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and WisdomTree Inc. Common Stock for 6 Days on average.
| MRVI | WT | |
|---|---|---|
Market Cap | $972.90M | $3.27B |
Volume | 4,325,710 | 2,488,313 |
Sector | Health | Financials |
52-Week High | $9.00 | $25.04 |
52-Week Low | $2.83 | $10.73 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $4.02B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
WisdomTree (WT) trades at $21.61, down 2.83% on the day, near the analyst low target of $21.30. The stock shows bearish technical signals with mixed oscillators, while fundamentals reveal strong profitability margins and consistent earnings beats. Recent news highlights WisdomTree's expansion into tokenized funds and new ETF launches, signaling growth initiatives.
The outlook is cautiously optimistic given analyst consensus favoring Buy ratings and a $26.05 price target, but risks include high valuation multiples and negative investing cash flow trends. Earnings momentum from recent beats supports upside potential, though investors face volatility from market sentiment and execution risks in new business lines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About WisdomTree Inc. Common Stock
WisdomTree provides exchange-traded products, model portfolios, and digital-asset-related products and services. Its digital offerings include tokenized funds, an institutional platform, and a blockchain-native wallet.
Read more on WT →
